CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--DiaKine Therapeutics, Inc. and Mediatech, Inc. today announced an agreement to market Lisofylline (LSF) to islet cell transplant centers worldwide. LSF is designed to improve the viability and insulin producing capabilities of harvested islet cells prior to transplant, potentially improving the success rate of the procedure.
